A Clinical Framework for Antithrombotic Review in Anticoagulated Patients With Stable Coronary Artery Disease: When Should Aspirin Be Stopped? - Cureus

Four late-breaking trials, presented at ESC Congress 2026 focused on post-acute coronary syndrome (ACS) antithrombotic therapy. LIBREXIA ACS examined adding the factor XIa inhibitor milvexian to antiplatelet therapy after ACS, PREMIUM looked at aspirin omission at the time of primary PCI for STEMI, SWITCH SWEDEHEART evaluated whether to switch from ticagrelor to prasugrel in ACS, and A-CLOSE compared clopidogrel monotherapy with extended dual antiplatelet therapy (DAPT) after high-risk PCI. LIBREXIA ACS: Can Factor XIa Inhibition Improve Outcomes After ACS?

A roar of laughter erupts from a crowd inside a large conference room at the De Vere Cranage Estate hotel. The joke? The idea that visiting the doctor could help treat a serious illness. On stage the controversial Australian proponent of natural remedies Barbara O’Neill is taking part in a question-and-answer session during a five-day wellness conference, where science mixes uncomfortably with Bible verse and potentially deadly pseudo-scientific practices. She is advising people attending at the event in Cheshire on a variety of medical ailments, and dismisses the use of antibiotics, vaccines or scientifically proven cancer treatment. Tickets for the residential retreat can cost up to £1,300. An undercover reporter for the Guardian attended for one day, observing four sessions covering topics including the immune system and one titled Barbara Under Attack. The audience’s rapturous laughter is prompted by a woman asking O’Neill if there is anything that could help her lupus, which she says has not responded well to the doctor’s treatments. “Yes, keep away from the doctor,” quips O’Neill.

News • Trial investigates combined benefits A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I

MALABO, Equatorial Guinea (AP) — With its torrential rains, tropical forests and omnipresent humidity, Equatorial Guinea provides the perfect conditions for mosquitoes to breed. For centuries, mosquito-borne diseases, in particular malaria, have dictated the fate of residents of this central African nation, impacting how they lived, worked and died. But Bioko island, off mainland Equatorial Guinea, has managed to sharply reduce malaria infections and deaths. Bioko, roughly half the size of Rhode Island, has used familiar tools: indoor spraying, mosquito nets and keeping control of the larvae population. Its success, however, has depended on something less easily replicated: two decades of painstaking data collection, sustained funding and workers going door to door to win residents' trust. Now the tiny, oil-rich country wants to bring that approach to its mainland and eliminate malaria altogether. But the expansion of Bioko's strategy presents formidable challenges, from porous international borders to the sheer scale of the territory.

A hospital that has implanted tiny pacemakers for 10 years has been recognised as a "centre of excellence". Northampton General Hospital said the honour, bestowed by the manufacturer, was for the way "it has pioneered" the fitting of the leadless pacemaker and for training other teams around the UK. The device is 93% smaller than traditional pacemakers, weighs about two grams and can be inserted in about 20 minutes. It is so small that it cannot be felt under the surface of the skin, the trust explained. The device, made by global US healthcare company Medtronic, has been used in Northampton since 2016 and in 2024 it became the first hospital trust in the UK to use the latest form. The trust has fitted it in about 300 patients so far. Staff Northampton General Hospital were treated with a cake to mark the achievement [NGH]Dr David Sharman, a consultant cardiologist who implanted the hospital's first device, said his team had been training specialist nurses, cardiac physiologists and radiographers from across England. "This kind of pacemaker is the future for pacemakers," he said. Do you have a story suggestion for Northamptonshire? Contact us below.